Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study

被引：0
|
作者：
Oh, D-Y. [1 ]
Meric-Bernstam, F. [2 ]
Makker, V. [3 ]
Oaknin, A. [4 ]
Banerjee, S. [5 ]
Gonzalez Martin, A. [6 ,7 ]
Jung, K. H. [8 ]
Lugowska, I. [9 ,10 ]
Manso, L. M. [11 ]
Manzano, A. [12 ]
Melichar, B. [13 ]
Siena, S. [14 ]
Stroyakovskiy, D. [15 ]
Fielding, A. [16 ]
Ma, Y. [17 ]
Puvvada, S. D.
Lee, J-Y. [18 ]
机构：
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[3] Mem Sloan Kettering Canc Ctr, Gynecol Med Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[4] Vall dHebron Inst Oncol, Hosp Univ Vall dHebron, Gynaecol Canc Programme, Barcelona, Spain
[5] Royal Marsden NHS Fdn Trust & Inst Canc Res, Gynaecol Unit, London, England
[6] Univ Navarra, Canc Ctr Clin, Med Oncol Dept, Madrid, Spain
[7] Univ Navarra, Canc Ctr Clin, Programme Solid Tumours CIMA, Madrid, Spain
[8] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[9] Maria Sklodowska Curie Natl Res Inst & Oncol Ctr, Early Phase Clin Trials Unit, Warsaw, Poland
[10] Maria Sklodowska Curie Natl Res Inst & Oncol Ctr, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland
[11] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[12] Hosp Clin San Carlos, Dept Med Oncol, Expt Therapeut Canc UTEC, Madrid, Spain
[13] Palacky Univ, Univ Hosp, Dept Oncol, Med Sch, Olomouc, Czech Republic
[14] Univ Milan, Dept Oncol, Piazza Osped Maggiore, Milan, Italy
[15] Moscow City Oncol Hosp 62, Healthcare Dept, Moscow, Russia
[16] AstraZeneca, Oncol R&D, Gaithersburg, MD USA
[17] AstraZeneca, Oncol R&D, Cambridge, England
[18] Yonsei Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.209
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
74MO
引用
收藏
页码：S1494 / S1495
页数：2
相关论文
共 50 条
  • [41] Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINYeLung02 (DL-02)
    Goto, Y.
    Goto, K.
    Kubo, T.
    Ninomiya, K.
    Kim, S-W.
    Ahn, M-J.
    Nakagawa, K.
    Hayashi, H.
    Shimizu, J.
    Kim, D-W.
    Yang, J. C-H.
    Kuo, C-H. S.
    Lee, K. H.
    Yang, T-Y.
    Pereira, K. M. C.
    Taguchi, A.
    Ali, A.
    Cheng, F-C.
    Yonemochi, R.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1666 - S1667
  • [42] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Im, Seock-Ah
    Iwata, Hiroji
    Curigliano, Giuseppe
    Kim, Sung-Bae
    Chiu, Joanne Wing-Yan
    Pedrini, Jose Luiz
    Li, Wei
    Yonemori, Kan
    Bianchini, Giampaolo
    Loi, Sherene
    Borges, Giuliano Santos
    Wang, Xian
    Bachelot, Thomas
    Nakatani, Shunsuke
    Ashfaque, Shahid
    Liang, Zhengkang
    Egorov, Anton
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
    Jerusalem, Guy Heinrich Maria
    Park, Yeon Hee
    Yamashita, Toshinari
    Hurvitz, Sara A.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Gonzalez, Xavier
    Hall, Peter S.
    You, Benoit
    Saura, Cristina
    Kim, Sung-Bae
    Osborne, Cynthia R. C.
    Sagara, Yasuaki
    Tokunaga, Eriko
    Liu, Yali
    Cathcart, Jillian
    Lee, Caleb C.
    Perrin, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
    Cortes, J.
    Kim, S-B.
    Chung, W-P.
    Im, S-A.
    Park, Y. H.
    Hegg, R.
    Kim, M. H.
    Tseng, L-M.
    Petry, V.
    Chung, C-F.
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Verma, S.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1287 - S1288
  • [45] Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)
    Li, B. T.
    Smit, E. F. F.
    Goto, Y.
    Nakagawa, K.
    Udagawa, H.
    Mazieres, J.
    Nagasaka, M.
    Bazhenova, L.
    Saltos, A. N.
    Felip, E.
    Pacheco, J. M.
    Perol, M.
    Paz-Ares, L.
    Saxena, K.
    Shiga, R.
    Cheng, Y.
    Acharyya, S.
    Shahidi, J.
    Planchard, D.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1323 - S1324
  • [46] Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study
    Hamilton, Erika
    Shapiro, Charles L.
    Petrylak, Daniel
    Boni, Valentina
    Martin, Miguel
    Del Conte, Gianluca
    Cortes, Javier
    Agarwal, Laila
    Arkenau, Hendrik-Tobias
    Tan, Antoinette R.
    Debruyne, Philip
    Minchom, Anna
    Rutten, Annemie
    Valdes-Albini, Frances
    Yu, Evan Y.
    Augustine, Bincy
    D'Amelio, Anthony, Jr.
    Barrios, Daniel
    Hurvitz, Sara A.
    CANCER RESEARCH, 2021, 81 (04)
  • [47] Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
    Powell, C. A.
    Modi, S.
    Iwata, H.
    Takahashi, S.
    Nie, K.
    Qin, A.
    Singh, J.
    Taitt, C.
    Verma, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S61 - S62
  • [48] Exposureefficacy and safety analysis of trastuzumab deruxtecan (T-DXd) in patients with advanced/metastatic HER2+breast cancer (BC): Analyses from Phase 3 Studies DESTINYBreast02 (DB-02) and DESTINYBreast03 (DB-03)
    Li, Claire
    Wada, Russ
    Li, Hanbin
    Kastrissios, Helen
    Abutarif, Malaz
    Garimella, Tushar
    Khatri, Amit
    CANCER RESEARCH, 2024, 84 (09)
  • [49] EVALUATION OF DRUG-DRUG INTERACTIONS (DDI) BETWEEN OATP1B/CYP3A INHIBITORS AND [FAM-] TRASTUZUMAB DERUXTECAN (T-DXD, DS 8201) IN HER2-EXPRESSING SOLID TUMORS.
    Kamiyama, E.
    Garimella, T.
    Bang, Y.
    Takahashi, S.
    LaCreta, F.
    Ishizuka, H.
    Abutarif, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S69 - S69
  • [50] Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with heavily pretreated HER2 positive advanced breast cancer: A retrospective single institution study
    Vosoughi, Elham
    Nafissi, Nellie
    Mahadevan, Aditya
    Lee, Seungshin
    Parajuli, Kritisha
    Rijal, Nejina
    Parajuli, Ritesh
    Mehta, Rita S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345